X
<
Article-1-2-1
Analyzing General Electric's 4Q17 Dividend

On December 9, 2017, General Electric, an industrial conglomerate, declared a quarterly cash dividend of $0.12 per share on its outstanding common stock.

Asian
Pre-Market Report: Global Markets Are Mixed on December 13

On December 13, the Shanghai Composite Index rose 0.68% and closed the day at 3,303.04. The SPDR S&P China (GXC) fell 1.3% on December 12.

SCG-stk-1
SCANA’s Nuclear Mess Continues to Push the Stock Down

The stock for SCANA (SCG), which is based in Cayce, South Carolina, is continuing to fall over its nuclear power plant issues. The stock fell more than 6% on December 11, 2017.

etf performance
How US Tax Reforms Could Impact the Healthcare Industry

The tax reform bills passed by the US House and Senate reduce the corporate tax rate from 35.0% to 20.0%. According to Credit Suisse, healthcare companies pay corporate taxes as high as 30.2%.

RECENT Healthcare RESEARCH

Novartis-revenues-1
Where Is Novartis Positioned after 3Q17?

In 3Q17, Novartis (NVS) reported revenues of ~$12.4 billion, which was ~2% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

Chart-08-1
Where Sanofi Stands after the 3Q17 Results

Sanofi’s 3Q17 earnings were released on November 2, 2017. It reported revenues of 9.05 billion euros for 3Q17, an operational growth of 4.7% YoY.

Part 1
What Investors Can Expect from PetMed Express in 2017

Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.

Graph-1-1-1
Who's Thanking Align Technology This November?

In 3Q17, Align Technology reported total revenues close to $385.3 million, which represents YoY growth of ~38.3% and QoQ growth of ~8.1%.

HIGHLIGHTS
Can Zimmer Biomet Recover after Disappointing 3Q17?

Zimmer Biomet Holdings (ZBH) reported sales of approximately $1.8 billion in 3Q17, which ended on September 30, 2017. The company released its 3Q17 results on November 1, 2017.

1
Key Takeaways from CVS Health’s 3Q17 Earnings

The Rhode Island–based CVS Health (CVS) reported its results for 3Q17 on Monday, November 6. The results relate to the three-month period that ended on September 30, 2017.

Celgene
How Is Celgene Positioned after Its 3Q17 Earnings?

In 3Q17, Celgene (CELG) generated revenues of $3.3 billion, which reflected ~10.0% growth year-over-year. Celgene reported an operating margin of ~59.5%.

Chart-01-Rev-EPS-1
The Truth behind Pfizer's 3Q17 Earnings

Pfizer (PFE) released its 3Q17 earnings on October 31, 2017, reporting another strong quarter in its Innovative Health business, with a 1% growth in revenues.

Roche-revenues-1
How Roche Is Positioned after 3Q17

In 3Q17, Roche Holding (RHHBY) generated revenues of 13.1 billion Swiss francs, which was a ~5% rise YoY. Revenues for its Pharmaceuticals segment rose ~4%, and its Diagnostics segment rose ~6%.

Graph-4-1
What Drives Sarepta Therapeutics' Growth

In this series, we’ll look at some key growth drivers for Sarepta Therapeutics.

Chart-1-Rev-1
Bristol-Myers Squibb’s Valuation after Its 3Q17 Earnings

Bristol-Myers Squibb’s (BMY) product portfolio includes drugs from various therapeutic areas including Cardiovascular, Virology, Immunoscience, Neuroscience, and Oncology. The chart below shows the revenues of Bristol-Myers Squibb since 4Q15. Because…

Chart-01-Rev-EPS-1
What to Expect from Sanofi’s 3Q17 Earnings

Analysts estimate that Sanofi’s gross profit margin will fall 1.2% to 70.6% during 3Q17 as compared to its gross profit margin of 71.8% during 3Q16.

Amgen-revenues-1
How Amgen Performed in 3Q17

In 3Q17, Amgen (AMGN) generated revenues of around $5.8 billion, a ~1% decline on a year-over-year (or YoY) basis and a ~1% decline on a quarter-over-quarter basis.

Graph-1-7-1
Sarepta Therapetics in 2017: Should Investors Be Interested?

On September 19, 2016, Sarepta Therapeutics’ (SRPT) Exondys 51 got approval from the FDA as a therapy for Duchenne muscular dystrophy in patients with a mutation in the dystrophin gene that is amenable to exon 51 skipping.

analyst-recommendations-3-1
Boston Scientific's 3Q17 Earnings—Tops Sales Estimates

Boston Scientific (BSX) released its 3Q17 earnings on October 26. On October 31, BSX received “buy” ratings from 19 of 25 analysts covering its stock.

highlights
Behind Baxter's 52-Week High

On the day of its 3Q17 results, the stock gained ~0.05%. The next day, BAX stock witnessed higher gains, triggered by investor confidence.

1
Checking Up on CVS Health ahead of 3Q17 Earnings

The Rhode Island–based CVS Health (CVS) is slated to release its 3Q17 results on Monday, November 6. Here’s what you need to know.

Graph-1-6-1
What's Driving Alnylam Pharmaceuticals?

On September 20, 2017, Alnylam Pharmaceuticals (ALNY) announced positive top-line results from phase three trial APOLLO.

Gilead-Sciences-revenues-1
Gilead Sciences: How 3Q17 Turned Out

In 3Q17, Gilead Sciences (GILD) generated revenues of $6.5 billion, which reflected a ~13% fall YoY (year-over-year) and a ~9% fall QoQ (quarter-over-quarter).

stock-price-6-1
Why Analysts Have a Positive View on Stryker

Stryker, one of the leading players in the orthopedic device industry, released its 3Q17 earnings results on October 26, 2017.

X

Please select a profession that best describes you: